These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 28034993)

  • 1. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the
    Ades L; Prebet T; Stamatoullas A; Recher C; Guieze R; Raffoux E; Bouabdallah K; Hunault M; Wattel E; Stalnikiewicz L; Toma A; Dombret H; Vey N; Sebert M; Gardin C; Chaffaut C; Chevret S; Fenaux P
    Haematologica; 2017 Apr; 102(4):728-735. PubMed ID: 28034993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
    Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
    Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
    Chen Y; Kantarjian H; Estrov Z; Faderl S; Ravandi F; Rey K; Cortes J; Borthakur G
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):341-4. PubMed ID: 22579233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
    Arcioni F; Roncadori A; Di Battista V; Tura S; Covezzoli A; Cundari S; Mecucci C;
    Eur J Haematol; 2018 Jul; 101(1):78-85. PubMed ID: 29569278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.
    Sekeres MA; Gundacker H; Lancet J; Advani A; Petersdorf S; Liesveld J; Mulford D; Norwood T; Willman CL; Appelbaum FR; List AF
    Blood; 2011 Jul; 118(3):523-8. PubMed ID: 21551228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.
    Adès L; Le Bras F; Sebert M; Kelaidi C; Lamy T; Dreyfus F; Eclache V; Delaunay J; Bouscary D; Visanica S; Turlure P; Bresler AG; Cabrol MP; Banos A; Blanc M; Vey N; Delmer A; Wattel E; Chevret S; Fenaux P
    Haematologica; 2012 Feb; 97(2):213-8. PubMed ID: 21993675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
    Giagounidis AA
    Semin Hematol; 2012 Oct; 49(4):312-22. PubMed ID: 23079061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
    Sugimoto Y; Sekeres MA; Makishima H; Traina F; Visconte V; Jankowska A; Jerez A; Szpurka H; O'Keefe CL; Guinta K; Afable M; Tiu R; McGraw KL; List AF; Maciejewski J
    J Hematol Oncol; 2012 Mar; 5():4. PubMed ID: 22390313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
    Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
    Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
    Platzbecker U; Braulke F; Kündgen A; Götze K; Bug G; Schönefeldt C; Shirneshan K; Röllig C; Bornhäuser M; Naumann R; Neesen J; Giagounidis A; Hofmann WK; Ehninger G; Germing U; Haase D; Wermke M
    Leukemia; 2013 Jun; 27(6):1403-7. PubMed ID: 23354011
    [No Abstract]   [Full Text] [Related]  

  • 12. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
    Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
    Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).
    Butrym A; Lech-Maranda E; Patkowska E; Kumiega B; Bieniaszewska M; Mital A; Madry K; Torosian T; Wichary R; Rybka J; Warzocha K; Mazur G
    BMC Cancer; 2015 Jul; 15():508. PubMed ID: 26152663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Daver N; Kantarjian H; Garcia-Manero G; Jabbour E; Borthakur G; Brandt M; Pierce S; Vaughan K; Ning J; Nogueras González GM; Patel K; Jorgensen J; Pemmaraju N; Kadia T; Konopleva M; Andreeff M; DiNardo C; Cortes J; Ward R; Craig A; Ravandi F
    Haematologica; 2017 Oct; 102(10):1709-1717. PubMed ID: 28729302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
    List A; Dewald G; Bennett J; Giagounidis A; Raza A; Feldman E; Powell B; Greenberg P; Thomas D; Stone R; Reeder C; Wride K; Patin J; Schmidt M; Zeldis J; Knight R;
    N Engl J Med; 2006 Oct; 355(14):1456-65. PubMed ID: 17021321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
    Giagounidis A; Mufti GJ; Mittelman M; Sanz G; Platzbecker U; Muus P; Selleslag D; Beyne-Rauzy O; te Boekhorst P; del Cañizo C; Guerci-Bresler A; Nilsson L; Lübbert M; Quesnel B; Ganser A; Bowen D; Schlegelberger B; Göhring G; Fu T; Benettaib B; Hellström-Lindberg E; Fenaux P
    Eur J Haematol; 2014 Nov; 93(5):429-38. PubMed ID: 24813620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
    Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E
    Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
    Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
    Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
    Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
    Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
    Narayan R; Garcia JS; Percival ME; Berube C; Coutre S; Gotlib J; Greenberg P; Liedtke M; Hewitt R; Regan K; Williamson C; Doykan C; Cardone MH; McMillan A; Medeiros BC
    Leuk Lymphoma; 2016; 57(3):609-15. PubMed ID: 26374199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.